Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Index
-
Market Cap
47.91M
Enterprise Value
22.39M
Income
-26.93M
Sales
0.80M
Book/sh
0.15
Cash/sh
0.16
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
39
IPO
Apr 24, 2019
P/E
-
Forward P/E
-
PEG
-
P/S
59.88
P/B
2.02
P/C
1.84
P/FCF
-
EV/EBITDA
-
EV/Sales
27.98
Quick Ratio
5.22
Current Ratio
5.22
Debt/Eq
0.02
LT Debt/Eq
0.00
Option/Short
Yes / Yes
EPS (ttm)
-0.17
EPS next Y
-0.03
EPS next Q
-0.02
EPS this Y
-13.53%
EPS next Y
54.38%
EPS next 5Y
-7.34%
EPS past 3/5Y
8.97% 38.96%
Sales past 3/5Y
- -
EPS Y/Y TTM
36.23%
Sales Y/Y TTM
57.97%
EPS Q/Q
16.51%
Sales Q/Q
-
Insider Own
0.00%
Insider Trans
-
Inst Own
35.56%
Inst Trans
-12.86%
ROA
-64.74%
ROE
-76.59%
ROIC
-113.56%
Gross Margin
-100.35%
Oper. Margin
-3800.24%
Profit Margin
-3367.41%
SMA20
2.04%
SMA50
-3.77%
SMA200
-6.28%
Trades
Shs Outstand
159.69M
Shs Float
159.69M
52W High
2.37 -87.34%
52W Low
0.20 50.00%
Volatility
6.10% 7.53%
ATR (14)
0.02
RSI (14)
48.73
Beta
0.19
Rel Volume
0.00
Avg Volume
1.24M
Volume
43
Perf Week
0.70%
Perf Month
-0.70%
Perf Quarter
-3.69%
Perf Half Y
26.05%
Perf YTD
-28.01%
Perf Year
-83.05%
Perf 3Y
-85.58%
Perf 5Y
-85.37%
Perf 10Y
-
Prev Close
0.31
Price
0.30
Change %
-1.64%
Consensus
Buy
Avg. Price Target
$2.00
Implied Upside
+566.7%
Analysts6incl. previous ratings
Rating Distribution4 Buy · 1 Hold · 1 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Aug 19, 2026Downgrade
JPM logoJJP Morgan
Neutral → Underweight
Mar 23, 2026Downgrade
JPM logoJJP Morgan
Overweight → Neutral
Dec 30, 2025Downgrade
JEF logoJJefferies
Buy → Hold$0.50+66.7%
Mar 27, 2025Initiated
JPM logoJJP Morgan
Overweight$7+2,233.3%
Dec 06, 2024Initiated
JEF logoJJefferies
Buy$7+2,233.3%
Jun 13, 2024Initiated
RRobert W. Baird
Outperform$8+2,566.7%
Oct 13, 2023Resumed
BBTIG Research
Buy$4+1,233.3%
Aug 12, 2022Initiated
CCantor Fitzgerald
Overweight$4+1,233.3%
May 05, 2021Initiated
BBTIG Research
Buy$10+3,233.3%
Apr 05, 2021Initiated
NNeedham
Buy$10+3,233.3%
Mereo BioPharma Group Plc is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that aim to improve outcomes for oncology and rare diseases. Its portfolio include Etigilimab (MPH-313), Alvelestat (MPH-966), Setrusumab (BPS-804), Navicixizumab (OMP-305B83), Acumapimod (BCT-197), and Leflutrozole (BGS-649). The company was founded by Denise Vera Scots-Knight, Charles Edward Sermon, Alastair Graham MacKinnon, and John P. Richard in March 10, 2015 and is headquartered in London, the United Kingdom.
Co-FounderDr. Denise Vera Scots-Knight Ph.D.
Co-FounderMr. Charles Edward Sermon
Chief Financial OfficerMs. Christine Fox CPA
Chief Scientific OfficerDr. John A. Lewicki Ph.D.
VP & Head of HRMs. Bal Lally